Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY19 results · Jan–Mar 2019
Ajanta Pharma reported revenue from operations of ₹515.16 crore and net profit of ₹88.89 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 515.16 | — | — | 485.11 | +6.2% |
| Other income | 1.63 | — | — | 4.41 | −63.0% |
| Total income | 516.79 | — | — | 489.52 | +5.6% |
| Profit before tax | 109.19 | — | — | 92.96 | +17.5% |
| Net profit for the period | 88.89 | — | — | 66.90 | +32.9% |
| Attributable to shareholders of the company | 88.83 | — | — | — | — |
| EPS, basic (₹) | 10.10 | — | — | 7.60 | +32.9% |
| Net margin (%) | 17.3 | — | 13.8 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 413.53 | — | — | 451.85 | −8.5% |
| Other income | 3.19 | — | — | 12.97 | −75.4% |
| Total income | 416.72 | — | — | 464.82 | −10.3% |
| Profit before tax | 52.01 | — | — | 125.70 | −58.6% |
| Net profit for the period | 41.37 | — | — | 95.47 | −56.7% |
| EPS, basic (₹) | 4.70 | — | — | 10.85 | −56.7% |
| Net margin (%) | 10.0 | — | 21.1 |
Consolidated
- Filed with BSE
- 02 May 2019, 12:48 IST
- Board meeting
- 30 Apr 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 May 2019, 12:48 IST
- Board meeting
- 30 Apr 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE